Compare Humana Inc (HUM) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs JPMorgan Chase & Co — how do they compare? Humana Inc trades at $373.38 (market cap $46.31B), while JPMorgan Chase & Co trades at $362.22 (market cap $956.39B). The key difference: JPMorgan Chase & Co is far larger — about 20.7× Humana Inc's market cap, and JPMorgan Chase & Co pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| HUM | JPM | |
|---|---|---|
Market Cap | $46.31B | $956.39B |
Sector | Health | Financials |
52-Week High | $409.42 | $359.79 |
52-Week Low | $163.67 | $282.84 |
Enterprise Value | $53.67B | — |
Dividend Yield | 0.92% | 1.67% |
Volume | — | 10,479,943 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $385.00, up 4.82% today, with a bullish technical outlook and analyst consensus price target of $399.53. Recent earnings beats in Q1 and Q2 2026, alongside revenue growth to $129.66 billion in 2025, support fundamentals, though net margins have compressed. The company is expanding its Medicaid business and targeting margin improvements by 2027.
The stock offers upside to consensus targets but faces risks from Medicare Advantage margin pressures and regulatory changes. Profitability trends are weak despite revenue growth, requiring successful cost management to meet 2028 targets. Institutional sentiment is mixed with a majority hold rating.
JPMorgan Chase & Co. (JPM) trades at $362.04, up 1.26% in the last session, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $374.18. Recent earnings beat expectations in Q1 and Q2 2026, with Q3 2026 results pending. The company maintains strong profitability metrics, including a net income margin of 33.38% and ROE of 18.43%, though cash flow trends show volatility amid macroeconomic uncertainties.
The stock presents a moderate buy opportunity with upside potential from earnings resilience and sector strength, but risks include geopolitical tensions, cybersecurity threats highlighted in recent news, and fluctuating cash flows. Investors should weigh analyst optimism against CEO warnings on economic challenges for balanced decision-making.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
